Pages that link to "Q43743058"

The following pages link to Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases (Q43743058):

Displaying 45 items.

• Antimalarial Drug Toxicity (Q22061779) (← links)
• Anti-inflammatory and immunosuppressive drugs and reproduction (Q28218219) (← links)
• Neonatal outcome in patients with rheumatic disease (Q33363243) (← links)
• Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases (Q33445361) (← links)
• Effects of chloroquine on viral infections: an old drug against today's diseases? (Q33973620) (← links)
• Ocular Toxicity in Children Exposedin Uteroto Antimalarial Drugs: Review of the Literature (Q34048726) (← links)
• Ocular side effects of anti-rheumatic medications: what a rheumatologist should know. (Q34080132) (← links)
• Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the "flying saucer" sign) (Q34245232) (← links)
• Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy (Q35205935) (← links)
• Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis (Q35877606) (← links)
• Malaria chemoprophylaxis: when should we use it and what are the options? (Q35917341) (← links)
• Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study. (Q35941677) (← links)
• Alternative modified infant-feeding practices to prevent postnatal transmission of human immunodeficiency virus type 1 through breast milk: past, present, and future (Q36391604) (← links)
• Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future (Q36592626) (← links)
• Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century (Q36880738) (← links)
• The management of rheumatic diseases in pregnancy (Q37047839) (← links)
• Management of early aggressive rheumatoid arthritis during pregnancy and lactation (Q37510901) (← links)
• Management of RA medications in pregnant patients (Q37511730) (← links)
• Transient increase of interferon-stimulated genes and no clinical benefit by chloroquine treatment during acute simian immunodeficiency virus infection of macaques (Q37686199) (← links)
• Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases (Q37738882) (← links)
• Hydroxychloroquine: from malaria to autoimmunity (Q37827403) (← links)
• Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy (Q37854742) (← links)
• Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management (Q37943826) (← links)
• Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy (Q38126540) (← links)
• High-risk pregnancy and the rheumatologist. (Q38283472) (← links)
• A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye. (Q38352048) (← links)
• Treatment of rheumatoid arthritis during pregnancy: present and future (Q38832618) (← links)
• Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients (Q39062828) (← links)
• Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation (Q41913288) (← links)
• Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty‐three cases compared with a control group (Q41915008) (← links)
• Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study (Q41917416) (← links)
• Antimalarial agents in pregnancy (Q45712596) (← links)
• Unconventional secretion of FABP4 by endosomes and secretory lysosomes. (Q46207582) (← links)
• Systemic sclerosis and pregnancy (Q46350918) (← links)
• Dose optimisation of chloroquine by pharmacokinetic modelling during pregnancy for the treatment of Zika virus infection (Q58614457) (← links)
• Current awareness in pharmacoepidemiology and drug safety (Q74069835) (← links)
• [Kidney, lupus and pregnancy] (Q78506325) (← links)
• Antimalarials: an update in rheumatic diseases (Q84600129) (← links)
• Treatment of cutaneous lupus erythematosus (Q84697085) (← links)
• Fetal pharmacotherapy 2: fetal arrhythmia (Q86774474) (← links)
• Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era (Q87866782) (← links)
• [Safety management of the treatment with antimalarial drugs in rheumatology. Interdisciplinary recommendations based on a systematic literature search] (Q89870913) (← links)
• Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations (Q95628416) (← links)
• Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials (Q98383294) (← links)
• A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment (Q104495235) (← links)